Literature DB >> 16864975

Characterization of human kallikreins 6 and 10 in ascites fluid from ovarian cancer patients.

Liu-Ying Luo1, Antoninus Soosaipillai, Linda Grass, Eleftherios P Diamandis.   

Abstract

OBJECTIVES: Human kallikreins 6 (hK6) and 10 (hK10) are secreted serine proteases. We previously found that hK6 and hK10 are highly overexpressed in epithelial ovarian tumors and demonstrated that serum levels of hK6 and hK10 are valuable biomarkers for ovarian cancer diagnosis and prognosis. Our aim is to purify and characterize these two kallikreins from ascites fluid of ovarian cancer patients.
METHODS: Protein concentrations of hK6 and hK10 in ovarian cancer ascites fluids were measured with ELISA-type immunoassays. hK6 and hK10 were purified from the ascites fluids with immunoaffinity columns, followed by reverse-phase high performance liquid chromatography. Purified hK6 and hK10 were then subjected to N-terminal sequencing. Enzymatic analyses were performed with synthetic fluorogenic peptides.
RESULTS: hK6 and hK10 were present in ovarian cancer ascites fluid at concentrations ranging from 0.2-571 and 0.7-220 microg/l, respectively. The majority of hK6 and hK10 in the ascites fluids were present in the free (uncomplexed) form. Both hK6 and hK10 purified from the ascites fluid were zymogens with a molecular mass of 30 kDa. Purified hK6 exhibited trypsin-like enzymatic activity, whereas no enzymatic activity was observed for purified hK10. The enzymatic activity of hK6 could be suppressed by a neutralizing monoclonal antibody.
CONCLUSIONS: The majority of hK6 secreted by the ovarian tumor cells into the ascites fluid are present in the uncomplexed, zymogen form, possessing weak trypsin-like enzymatic activity. All hK10 present in ovarian cancer ascites fluids are in the uncomplexed, zymogen form and have no detectable enzymatic activity. Copyright (c) 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16864975     DOI: 10.1159/000094693

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  8 in total

1.  Upregulation and secretion of kallikrein-related peptidase 6 (KLK6) in gastric cancer.

Authors:  Jin Ju Kim; Jong-Tae Kim; Hyo Ran Yoon; Min Ah Kang; Joo Heon Kim; Young-Ha Lee; Jae Wha Kim; Seon-Jin Lee; Eun Young Song; Pyung Keun Myung; Hee Gu Lee
Journal:  Tumour Biol       Date:  2012-02-29

2.  Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers.

Authors:  Shalini Makawita; Chris Smith; Ihor Batruch; Yingye Zheng; Felix Rückert; Robert Grützmann; Christian Pilarsky; Steven Gallinger; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2011-06-07       Impact factor: 5.911

3.  Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer.

Authors:  N M A White; T-F F Chow; S Mejia-Guerrero; M Diamandis; Y Rofael; H Faragalla; M Mankaruous; M Gabril; A Girgis; G M Yousef
Journal:  Br J Cancer       Date:  2010-03-30       Impact factor: 7.640

4.  Clinical significance and novel mechanism of action of kallikrein 6 in glioblastoma.

Authors:  Kristen L Drucker; Alex R Paulsen; Caterina Giannini; Paul A Decker; Sachiko I Blaber; Michael Blaber; Joon H Uhm; Brian P O'Neill; Robert B Jenkins; Isobel A Scarisbrick
Journal:  Neuro Oncol       Date:  2013-01-10       Impact factor: 12.300

5.  Kallikreins 5, 6 and 10 differentially alter pathophysiology and overall survival in an ovarian cancer xenograft model.

Authors:  David Pépin; Zhong-Qi Shao; Geneviève Huppé; Andrea Wakefield; Chee-Wui Chu; Zahra Sharif; Barbara C Vanderhyden
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

6.  Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.

Authors:  Donavon Hiss
Journal:  J Oncol       Date:  2012-02-06       Impact factor: 4.375

7.  Evolution of the plasma and tissue kallikreins, and their alternative splicing isoforms.

Authors:  Vassiliki Lila Koumandou; Andreas Scorilas
Journal:  PLoS One       Date:  2013-07-10       Impact factor: 3.240

8.  Structural basis for the Zn2+ inhibition of the zymogen-like kallikrein-related peptidase 10.

Authors:  Mekdes Debela; Viktor Magdolen; Wolfram Bode; Hans Brandstetter; Peter Goettig
Journal:  Biol Chem       Date:  2016-12-01       Impact factor: 3.915

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.